Prostatic Diseases

03/01/2006 - "It was concluded that Goshajinkigan was effective for pollakisuria with prostatic disease, and the administration of the agent for 8 weeks or longer was needed to improve lower urinary tract symptoms."
06/01/2008 - "We investigated the efficacy of Goshajinkigan in 25 patients with prostatic disease in whom pollakisuria was not improved by treatment with drugs for lower urinary tract symptoms. "
06/01/2008 - "[Effect of Goshajinkigan on storage symptoms in prostatic disease--fundamental researches of Chinese herbal medicine for voiding dysfunction and its future aspects]."

10/01/2008 - "Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases."
05/01/1997 - "This study was designed to evaluate the distribution of prostate-specific antigen (PSA) levels of men in a mass screening program for prostatic disease. "
01/01/1994 - "To identify the effect of orgasm on serum prostate-specific antigen (PSA) levels, a prospective trial before and after orgasm was performed in 14 healthy colleagues aged 32-62 years (mean, 44.4 years) with no evidence of prostatic disease. "
12/01/1987 - "[Clinical studies of gamma-seminoprotein in prostatic disease. "
12/01/1987 - "[Clinical studies of gamma-seminoprotein in prostatic disease. "

04/23/1999 - "In contrast, lifetime exposure to 5% flaxseed reduced adult relative prostate weight and cell proliferation, suggesting potential protection against prostatic disease, although sex hormone levels were unaffected. "
08/01/2012 - "Thus, the results revealed different distribution pattern of steroid hormone receptors in each one of the prostatic lobes in senescence, especially in the prostate dorsal lobe and coagulating gland, which is a fundamental factor due to the fact that major prostatic diseases occur in a later period of life."
08/01/2011 - "The development and progression of prostatic diseases and their relation to hormone therapy is still unclear. "
10/13/1951 - "[Hormone therapy of prostatic disease]."
01/01/2008 - "The aim of the present study is to determine the expression of Gal-3 in prostate tissue emerging from a benign to a malignant, in the beginning hormone-sensitive and finally hormone-refractory status to further elucidate the role of this carbohydrate-binding protein for the pathogenesis and/or progression of malignant prostatic disease. "

09/01/2011 - "The aim of this study was to determine the prevalence of human papillomavirus (HPV) types in tissue and HPV antibodies in prostatic disease. "
09/01/2011 - "Antibodies against HPV-1, HPV-4, HPV-6 and HPV-11 were significantly higher in the group of males with prostatic disease. "
09/01/2011 - "Serology data showed no significant increase in levels of antibodies against any of the HPV-18 proteins tested for in prostatic disease patients. "
09/01/2008 - "Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases."
09/15/2007 - "The similarity of baboon prostate to its human counterpart and the fact that human antibodies (AMACR, PSA, basal keratin) are reactive to baboon prostatic proteins indicates that the baboon is a promising model for human prostatic diseases."

08/20/2009 - "Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease."
04/01/2001 - "Potentially useful biomarkers for prostate chemoprevention are associated with histologic, proliferative, differentiation-related, biochemical, and genetic/regulatory features of prostatic disease. "
07/01/2014 - "The most studied prostatic inflammation biomarkers detected in biological fluids are also presented, together with their potential roles in the diagnosis and prognosis of prostatic disease. "
01/01/2013 - "To assess the PBCDR we did all of the following: 1) Identified biomarkers that are related to PC and have the capability of improving the efficiency of PC screening; 2) Developed statistical models to determine which can best predict the probability of PC; 3) Compared each potential model to PSA alone using Receiver Operator Characteristic (ROC) curves, to evaluate for improved overall effectiveness in PC detection and reduction in (negative) biopsies; and 4) Evaluated dose-response relationships between specified lab biomarkers (surrogates for extra-prostatic disease development) and PC progression. "
04/01/2015 - "Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases."

12/01/2006 - "Botulinum-A toxin: an exciting new treatment option for prostatic disease."
09/01/2007 - "Botulinum toxin type A (BTX-A) has been used to treat urethral and prostatic diseases (off-label uses). "

09/01/2013 - "Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases."
03/01/2001 - "All the compounds were also tested on 17 alpha-hydroxylase/C17,20-lyase (P450 17), an enzyme of therapeutic interest for the treatment of prostatic diseases. "
09/01/2013 - "5α-Reductase is primarily of interest in benign prostatic disease, though some role in the chemoprevention of prostatic carcinoma have been considered, whereas the 17α-hydroxylase/17,20-lyase (CYP17) enzyme is of interest in the treatment of malignant disease. "

05/01/2007 - "In fifty six (56) serum samples which were collected from 'The Lab' and having other prostatic diseases, 49 (87.5%) had PSA within normal range (< or =4 ng/ml). "
05/01/2007 - "The other 56 samples were collected from patients having other prostatic diseases and advised PSA tests by physicians and urologists from 'The Lab' Karachi. "
01/01/2013 - "To assess the PBCDR we did all of the following: 1) Identified biomarkers that are related to PC and have the capability of improving the efficiency of PC screening; 2) Developed statistical models to determine which can best predict the probability of PC; 3) Compared each potential model to PSA alone using Receiver Operator Characteristic (ROC) curves, to evaluate for improved overall effectiveness in PC detection and reduction in (negative) biopsies; and 4) Evaluated dose-response relationships between specified lab biomarkers (surrogates for extra-prostatic disease development) and PC progression. "

08/01/2014 - "These findings confirm that impaired peripheral clearance of glucocorticoids can cause 'relative adrenal insufficiency' in mice, an observation with important implications for patients with critical illness or hepatic failure, and for patients receiving 5α-reductase inhibitors for prostatic disease. "

09/01/2008 - "Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases."

05/01/1994 - "This contrasts to our previous studies in which excisional prostatectomy reduced maximal urethral closure pressure (MUCP) in dogs without prostatic disease. "
11/01/1987 - "In this study, urodynamic alterations after prostatectomy in 10 dogs without clinical prostatic disease were evaluated. "
06/01/1998 - "However, regardless of the type of prostatectomy, whether it be transurethral, radical retropubic or radical perineal prostatectomy, or the nature of the prostatic disease, several risk factors are common to all. "
10/01/1997 - "Although most dogs with severe prostatic disease do not urinate normally before surgery, nearly all dogs resume normal micturition after partial prostatectomy. "
05/01/1994 - "In an attempt to reduce postoperative incontinence associated with excisional prostatectomy and the recurrence of prostatic disease after less radical surgeries, a new technique for subtotal prostatectomy was developed using an ultrasonic surgical aspirator. "

09/01/1990 - "In a clinical study, complications associated with subtotal prostatectomy with the Nd:YAG laser (n = 6) were compared with complications associated with prostatic drainage (n = 6) in dogs with prostatic disease. "
06/01/2006 - "To report the 3-year results and analyse whether total prostate-specific antigen (tPSA) levels and prostate volume before treatment can predict the level of clinical efficacy of photoselective vaporization prostatectomy (PVP) for treating obstructive benign prostatic disease, as high-power potassium-titanyl-phosphate (KTP) laser prostatectomy was previously shown to be safe and to efficiently vaporize prostatic adenoma secondary to benign prostatic hyperplasia (BPH), with minimal bleeding and morbidity. "

10/01/2010 - "Laser ablation of the prostate: a safe effective treatment of obstructive benign prostatic disease."
10/31/1998 - "The CLasP study comprises three linked multicentre, pragmatic randomised controlled trials evaluating the effectiveness and cost effectiveness of laser therapy, standard surgery, and conservative management for men with lower urinary tract symptoms or urinary retention, or both, related to benign prostatic disease. "

07/01/1977 - ""Blind" perurethral cryosurgery has been used and has been shown to be effective in relieving urethral outflow obstruction, particularly in the second series of 178 patients with benign prostatic disease in which a simple "rule of thumb" technique was used."
01/01/1976 - "Cryosurgery of the prostate became one of the routine procedures in the treatment of the prostatic diseases."
01/01/2000 - "Cryosurgery for the treatment of prostatic disease, a technique that originated in the mid-1960s and was almost abandoned in the mid-1970s, has re-emerged in the 1990s for the treatment of cancer of the prostate. "
04/01/1972 - "[Cryosurgery of prostatic diseases and bladder neoplasms]."

04/01/1993 - "[Local hyperthermia in the treatment of benign prostatic diseases]."
11/01/1992 - "Local hyperthermia for benign and malignant prostatic disease remains largely empirical. "
11/01/1992 - "Local hyperthermia for prostatic disease: in vitro studies on human prostatic cancer cell lines."
01/01/1995 - "[Microwave hyperthermia and thermotherapy in the treatment of prostatic diseases]."